Sun
Mon
Tue
Wed
Thu
Fri
Sat
Black outlined circle on a white background.
Sun
Mon
Tue
Wed
Thu
Fri
Sat

We conduct research and educational initiatives in regenerative science, examining cellular and molecular mechanisms relevant to molecular biology, recovery, and function.


The Cognify Clinical Trial Program is a nationwide, FDA-authorized Expanded Access trial for TB-006 — an investigational monoclonal antibody targeting galectin-3, a critical immune molecule at the crossroads of neuroinflammation and protein misfolding in Alzheimer’s disease.


Unlike traditional trials, Cognify is structured to allow eligible clinics to provide TB-006 under compassionate use, offering a treatment



Scientist in lab coat and goggles looking into a microscope. Blue gloves, computer screen, and lab equipment visible.
Doctor injecting a patient's knee in a medical exam room.

At Promethium Research Center, we offer lead focused research in Alzheimer’s disease, guided by science and patient-centered care.

Dr. Alberto Rivera, MD, FAAPMR, is an internationally recognized speaker in genomics, cell biology, nutrigenomics, an the integration of these disciplines with current standards of care.


He shares his clinical expertise at scientific conferences and professional forums worldwide.


He is also the author of Primal Fuel: The Ultimate Guide.

Three DNA double helix strands in white on a dark blue background.

Patient Testimonial

Participating in the TB006 research study gave us confidence that we were contributing to meaningful scientific progress. The research team was professional, attentive, and transparent throughout the process

Black vertical line on white background.
Alberto Rivera MD

Dr. Rivera has  more than two decades of been actively working with molecular cell technologies, with a strong focus on their application in inflammation . His work in this area centers on cellular repair, tissue recovery, and biologically driven approaches to injury and disease management  grounded in scientific rigor and translational relevance.

Elderly couple on a swing; man pushing, woman smiling. Fall colors in background with house.

Why Should I Participate in the Cognify Trial? 



  • The study medication is called TB006, which is a novel monoclonal antibody therapy targeting Galectin-3; a protein implicated in neuroinflammation and cognitive decline in Alzheimer’s disease. TB006 is designed to neutralize this protein’s damaging effects, with the goal of slowing or halting disease progression by reducing brain inflammation and

     improving neuronal survival.

  • You will be treated by a doctor at a nationally renowned medical center.

  • You will be helping to find an effective treatment for Alzheimer’s and dementia for patients like you. 


Under the scientific leadership of Dr. Al Rivera, our work advances molecular  cell pathways applications and dedicated research in Alzheimer’s disease.